Resource Summary Report

Generated by dkNET on Sep 3, 2026

CD137 (4-1BB) Monoclonal Antibody (17B5), PE-Cyanine7, eBioscience

RRID:AB_2573398
Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 25-1371-82, RRID:AB_2573398)

Antibody Information

URL: http://antibodyregistry.org/AB_2573398

Proper Citation: (Thermo Fisher Scientific Cat# 25-1371-82, RRID:AB_2573398)

Target Antigen: CD137 (4-1BB)

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: Flow

Antibody Name: CD137 (4-1BB) Monoclonal Antibody (17B5), PE-Cyanine7, eBioscience

Description: This monoclonal targets CD137 (4-1BB)

Target Organism: mouse

Clone ID: Clone 17B5

Defining Citation: PMID:15294956

Antibody ID: AB_2573398

Vendor: Thermo Fisher Scientific

Catalog Number: 25-1371-82

Alternative Catalog Numbers: 25-1371

Record Creation Time: 20251213T073800+0000

Record Last Update: 20260828T164048+0000

Ratings and Alerts

No rating or validation information has been found for CD137 (4-1BB) Monoclonal Antibody (17B5), PE-Cyanine7, eBioscience.

No alerts have been found for CD137 (4-1BB) Monoclonal Antibody (17B5), PE-Cyanine7, eBioscience.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Pang J, et al. (2026) Law-NQO1 redox boosts the pentose phosphate pathway to confer stem-like properties and antitumor durability in effector CD8+ T cells. Cell chemical biology, 33(3), 321.

Fujino T, et al. (2026) Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias. Cancer discovery.

Lee KJ, et al. (2024) IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T??cell engager immunotherapy. Cell reports. Medicine, 5(5), 101567.

Ziblat A, et al. (2024) Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell reports, 43(5), 114141.

Thumkeo D, et al. (2022) PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment. Cell reports, 39(10), 110914.